NCT00950300 2018-01-23A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast CancerHoffmann-La RochePhase 3 Completed596 enrolled 31 charts 1 FDA